BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 26338826)

  • 1. SETD2 histone modifier loss in aggressive GI stromal tumours.
    Huang KK; McPherson JR; Tay ST; Das K; Tan IB; Ng CC; Chia NY; Zhang SL; Myint SS; Hu L; Rajasegaran V; Huang D; Loh JL; Gan A; Sairi AN; Sam XX; Dominguez LT; Lee M; Soo KC; Ooi LL; Ong HS; Chung A; Chow PK; Wong WK; Selvarajan S; Ong CK; Lim KH; Nandi T; Rozen S; Teh BT; Quek R; Tan P
    Gut; 2016 Dec; 65(12):1960-1972. PubMed ID: 26338826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathological and molecular features of a large cohort of gastrointestinal stromal tumors (GISTs) and review of the literature: BRAF mutations in KIT/PDGFRA wild-type GISTs are rare events.
    Huss S; Pasternack H; Ihle MA; Merkelbach-Bruse S; Heitkötter B; Hartmann W; Trautmann M; Gevensleben H; Büttner R; Schildhaus HU; Wardelmann E
    Hum Pathol; 2017 Apr; 62():206-214. PubMed ID: 28159677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rhabdoid morphology in gastrointestinal stromal tumours (GISTs) is associated with PDGFRA mutations but does not imply aggressive behaviour.
    Schaefer IM; Ströbel P; Cameron S; Beham A; Otto C; Schildhaus HU; Agaimy A
    Histopathology; 2014 Feb; 64(3):421-30. PubMed ID: 24266839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aberrant DNA methylation associated with aggressiveness of gastrointestinal stromal tumour.
    Okamoto Y; Sawaki A; Ito S; Nishida T; Takahashi T; Toyota M; Suzuki H; Shinomura Y; Takeuchi I; Shinjo K; An B; Ito H; Yamao K; Fujii M; Murakami H; Osada H; Kataoka H; Joh T; Sekido Y; Kondo Y
    Gut; 2012 Mar; 61(3):392-401. PubMed ID: 21708825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GIST Manifesting as a Retroperitoneal Tumor: Clinicopathologic Immunohistochemical, and Molecular Genetic Study of 112 Cases.
    Miettinen M; Felisiak-Golabek A; Wang Z; Inaguma S; Lasota J
    Am J Surg Pathol; 2017 May; 41(5):577-585. PubMed ID: 28288036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted ultra-deep sequencing unveils a lack of driver-gene mutations linking non-hereditary gastrointestinal stromal tumors and highly prevalent second primary malignancies: random or nonrandom, that is the question.
    Lai BR; Wu YT; Kuo YC; Hsu HC; Chen JS; Chen TC; Wu RC; Chiu CT; Yeh CN; Yeh TS
    Oncotarget; 2016 Dec; 7(50):83270-83277. PubMed ID: 27806309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular biomarkers for prognosis of gastrointestinal stromal tumor.
    Liu X; Chu KM
    Clin Transl Oncol; 2019 Feb; 21(2):145-151. PubMed ID: 30003531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutations in SETD2 and genes affecting histone H3K36 methylation target hemispheric high-grade gliomas.
    Fontebasso AM; Schwartzentruber J; Khuong-Quang DA; Liu XY; Sturm D; Korshunov A; Jones DT; Witt H; Kool M; Albrecht S; Fleming A; Hadjadj D; Busche S; Lepage P; Montpetit A; Staffa A; Gerges N; Zakrzewska M; Zakrzewski K; Liberski PP; Hauser P; Garami M; Klekner A; Bognar L; Zadeh G; Faury D; Pfister SM; Jabado N; Majewski J
    Acta Neuropathol; 2013 May; 125(5):659-69. PubMed ID: 23417712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic Regulation of CD133 in Gastrointestinal Stromal Tumors.
    Geddert H; Braun A; Kayser C; Dimmler A; Faller G; Agaimy A; Haller F; Moskalev EA
    Am J Clin Pathol; 2017 May; 147(5):515-524. PubMed ID: 28398518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gastrointestinal stromal tumours (GISTs): a clinicopathological and molecular study of 66 cases.
    Koay MH; Goh YW; Iacopetta B; Grieu F; Segal A; Sterrett GF; Platten M; Spagnolo DV
    Pathology; 2005 Feb; 37(1):22-31. PubMed ID: 15875730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression profiling of GIST: CD133 is associated with KIT exon 11 mutations, gastric location and poor prognosis.
    Arne G; Kristiansson E; Nerman O; Kindblom LG; Ahlman H; Nilsson B; Nilsson O
    Int J Cancer; 2011 Sep; 129(5):1149-61. PubMed ID: 21064103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The expression of hematopoietic progenitor cell antigen CD34 is regulated by DNA methylation in a site-dependent manner in gastrointestinal stromal tumours.
    Bure I; Braun A; Kayser C; Geddert H; Schaefer IM; Cameron S; Ghadimi MB; Ströbel P; Werner M; Hartmann A; Wiemann S; Agaimy A; Haller F; Moskalev EA
    Int J Cancer; 2017 Dec; 141(11):2296-2304. PubMed ID: 28744850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic alterations in cell cycle regulation-associated genes may promote primary progression of gastrointestinal stromal tumors.
    Li P; Li M; Wang K; Liu Y; Wang Y; Zhao D; Chai J; Ma J; Li X; Wei J; Fan L; Zhang F; Ye J; Yan Q; Guo S; Wang Z
    Lab Invest; 2020 Mar; 100(3):426-437. PubMed ID: 31570771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SETD2 alterations and histone H3K36 trimethylation in phyllodes tumor of breast.
    Tsang JY; Lai ST; Ni YB; Shao Y; Poon IK; Kwan JS; Chow C; Shea KH; Tse GM
    Breast Cancer Res Treat; 2021 Jun; 187(2):339-347. PubMed ID: 33844099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. V600E BRAF mutations are alternative early molecular events in a subset of KIT/PDGFRA wild-type gastrointestinal stromal tumours.
    Agaimy A; Terracciano LM; Dirnhofer S; Tornillo L; Foerster A; Hartmann A; Bihl MP
    J Clin Pathol; 2009 Jul; 62(7):613-6. PubMed ID: 19561230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined DNA methylation and gene expression profiling in gastrointestinal stromal tumors reveals hypomethylation of SPP1 as an independent prognostic factor.
    Haller F; Zhang JD; Moskalev EA; Braun A; Otto C; Geddert H; Riazalhosseini Y; Ward A; Balwierz A; Schaefer IM; Cameron S; Ghadimi BM; Agaimy A; Fletcher JA; Hoheisel J; Hartmann A; Werner M; Wiemann S; Sahin O
    Int J Cancer; 2015 Mar; 136(5):1013-23. PubMed ID: 25046773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-resolution profiling of histone h3 lysine 36 trimethylation in metastatic renal cell carcinoma.
    Ho TH; Park IY; Zhao H; Tong P; Champion MD; Yan H; Monzon FA; Hoang A; Tamboli P; Parker AS; Joseph RW; Qiao W; Dykema K; Tannir NM; Castle EP; Nunez-Nateras R; Teh BT; Wang J; Walker CL; Hung MC; Jonasch E
    Oncogene; 2016 Mar; 35(12):1565-74. PubMed ID: 26073078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis.
    Martinelli G; Mancini M; De Benedittis C; Rondoni M; Papayannidis C; Manfrini M; Meggendorfer M; Calogero R; Guadagnuolo V; Fontana MC; Bavaro L; Padella A; Zago E; Pagano L; Zanotti R; Scaffidi L; Specchia G; Albano F; Merante S; Elena C; Savini P; Gangemi D; Tosi P; Ciceri F; Poletti G; Riccioni L; Morigi F; Delledonne M; Haferlach T; Cavo M; Valent P; Soverini S
    Leukemia; 2018 Jan; 32(1):139-148. PubMed ID: 28663576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gastrointestinal stromal tumors presenting as omental masses--a clinicopathologic analysis of 95 cases.
    Miettinen M; Sobin LH; Lasota J
    Am J Surg Pathol; 2009 Sep; 33(9):1267-75. PubMed ID: 19440146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SETD2 as a regulator of N6-methyladenosine RNA methylation and modifiers in cancer.
    Kumari S; Muthusamy S
    Eur J Cancer Prev; 2020 Nov; 29(6):556-564. PubMed ID: 33021769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.